Please login to the form below

Not currently logged in
Email:
Password:

High staff turnover found in CROs

US research firm warns that pharma companies will assess CRO turnover rates

Clinical research organisations (CROs) in the US are experiencing a dramatically high level of employee turnover, according to a new study.

The CRO Industry Global Compensation and Turnover Survey by research firm HR+Survey, found that employees at CROs are leaving for new jobs at significantly higher rates than their counterparts in other industries.

The survey results showed that in 2012 the CRO industry experienced 12.5 per cent 'voluntary separation' (moving to find positions with higher compensation and/or greater opportunities), compared with a national voluntary turnover rate average of 1.5 per cent (US Bureau of Labor Statistics).

The HR+Survey report warned that high employee turnover rates could be damaging for CROs because pharmaceutical companies will assess turnover rates during the decision-making process for outsourcing clinical trials.

"The survey indicates that there is tremendous movement within the CRO industry," began Judy Canavan, partner at HR+Survey.

"The reasons remain multi-faceted, but these numbers continue to be a concern in an industry that has seen double-digit growth and where companies' greatest assets are their talent.

"CROs should consider solutions that foster retention of talent and institutional knowledge, including the use of stay bonuses, which are earned over time," she added.

Currently, 65 per cent of the country's CROs offer sign-on bonuses to attract talent, yet only 29 per cent offer retention bonuses as an incentive for retaining employees.

In addition, the target for annual incentives and projected long-term incentive (LTI) levels were found to be considerably lower for CROs compared to other industries. For example, CRO executives with a $250,000 salary were eligible for an average target annual incentive of 26 per cent and LTI of 35 per cent, while counterparts in other industries could expect annual incentives and LTIs of 44 and 51 per cent, respectively.

"This should send a strong message to CRO executives who have the opportunity to implement strategic solutions, including increasing the use of performance based incentives, to retain and motivate talent without having to increase fixed costs," Canavan continued.

"As we move into developing our 2013 survey, CRO leaders should consider participating in this research to more fully understand the impact of their compensation plans," she said.

11th April 2013

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics